NOVARTIS INDIA LIMITED

Markets established pharmaceutical brands in India across pain (Voveran), calcium supplementation (Calcium Sandoz, Macalvit, Citromacalvit), neurosciences (Tegrital), gynaecology and transplant immunology. For FY26, revenue from operations stood at Rs 354.33 crore with net profit of Rs 93.18 crore and total assets of Rs 978.27 crore. In Q1 FY27, revenue from operations rose to INR 1,038.1 million from INR 875.5 million, with PAT of INR 322.1 million and the company reporting zero outstanding debt. On July 29, 2026, ChrysCapital-backed entities (WaveRise Investments, ChrysCapital Fund X, Two Infinity Partners) completed the acquisition of Novartis AG's 70.68% stake (1,74,50,680 equity shares) for about Rs 1,376.89 crore. Under new management, the board approved a 5-year distribution deal with Novartis Pharma Services AG, a brand license for Tegrital, and the assignment of the Voveran, Macalvit and Citromacalvit trademarks, with a new corporate identity and website (nilpharma.co.in) to follow. Stated cost categories in FY26 were employee costs at 5.9% of revenue and other operating expenses at 11.5%, with depreciation at 0.6% and capex at 0.1%.